Compare Medpace Holdings Inc (MEDP) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Skyworks Solutions Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Skyworks Solutions Inc trades at $61.05 (market cap $8.99B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SWKS | |
|---|---|---|
Market Cap | $15.08B | $8.99B |
Sector | Technology | Technology |
52-Week High | $620.59 | $83.40 |
52-Week Low | $308.88 | $52.50 |
Enterprise Value | $14.55B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Skyworks Solutions (SWKS) trades at $59.83, up 0.88% on the day, with a bearish technical signal but strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue has declined from $5.5B in 2022 to $4.1B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in AI and EV sectors and an ongoing legal investigation.
The outlook is mixed: analyst consensus is bullish with a $75.88 price target (58.34% buy ratings), but technicals and declining revenue pose risks. Key opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal scrutiny. The stock offers a dividend yield above 4%, supported by cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
